Revance Therapeutics Inc. (NASDAQ:RVNC)’s share price traded up 5% during trading on Wednesday . The company traded as high as $13.95 and last traded at $13.79, with a volume of 95,311 shares traded. The stock had previously closed at $13.13.

A number of equities analysts recently commented on the company. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $35.00 price target (down from $54.00) on shares of Revance Therapeutics in a research note on Tuesday, June 14th. SunTrust Banks Inc. decreased their target price on Revance Therapeutics from $46.00 to $22.00 and set a “buy” rating for the company in a research note on Tuesday, June 14th. Zacks Investment Research upgraded Revance Therapeutics from a “hold” rating to a “buy” rating and set a $15.00 target price for the company in a research note on Wednesday, July 13th. Guggenheim restated a “buy” rating and issued a $55.00 target price on shares of Revance Therapeutics in a research note on Tuesday, June 14th. Finally, Brean Capital restated a “buy” rating on shares of Revance Therapeutics in a research note on Saturday, June 4th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Revance Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $39.60.

The firm’s market cap is $386.28 million. The firm’s 50 day moving average price is $14.87 and its 200-day moving average price is $18.43.

Revance Therapeutics (NASDAQ:RVNC) last posted its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.83) by $0.12. During the same quarter in the prior year, the firm posted ($0.65) earnings per share. Equities analysts forecast that Revance Therapeutics Inc. will post ($3.53) EPS for the current year.

A number of hedge funds have bought and sold shares of the stock. California State Teachers Retirement System boosted its stake in Revance Therapeutics by 19.3% in the fourth quarter. California State Teachers Retirement System now owns 33,966 shares of the biopharmaceutical company’s stock worth $1,160,000 after buying an additional 5,492 shares during the last quarter. Russell Frank Co acquired a new stake in Revance Therapeutics during the fourth quarter worth $1,384,000. Finally, Jennison Associates boosted its stake in Revance Therapeutics by 0.8% in the third quarter. Jennison Associates now owns 78,156 shares of the biopharmaceutical company’s stock worth $2,326,000 after buying an additional 603 shares during the last quarter.

Revance Therapeutics, Inc is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.